BBLG earnings: next report 2026-08-13, real EPS beat/miss history, P/E -0.40. Updated 2026-07-23.
Bone Biologics (BBLG) Research Hub
Bone Biologics (BBLG) trades on NASDAQ, US in the Healthcare (Biotechnology) sector. As of 2026-09-11, shares last closed at 0.5508 USD (-0.58%), in a range — insufficient history for 200-DMA. Valuation: trailing P/E -0.40, market cap 0.00B. This hub links to the full technical, earnings and options research available for BBLG.
Last updated 2026-09-11 · Source: FMP end-of-day prices (adjusted); indicators computed by SniperIQ
| Sector | Healthcare (Biotechnology) |
|---|---|
| Exchange | NASDAQ, US |
| Last close | 0.5508 USD (-0.58%) |
| 52-week range | 0.54367 USD – 1.54 USD |
| Trend regime | Range |
| 14-day RSI | 5.1 (Oversold) |
| Trailing P/E | -0.40 |
| Market cap | 0.00B |
| Dividend yield | 0.00% |
| Next earnings | 2026-08-13 |
Available research for BBLG
Covered Call on BBLG: how it works, illustrative setup around the real 0.5508 USD price, max profit/loss, breakeven and when to use it. Educational.
Iron Condor on BBLG: how it works, illustrative setup around the real 0.5508 USD price, max profit/loss, breakeven and when to use it. Educational.
Protective Put on BBLG: how it works, illustrative setup around the real 0.5508 USD price, max profit/loss, breakeven and when to use it. Educational.
BBLG technical analysis: range, last 0.5508 USD, RSI 5.1, 52w range 0.54367 USD–1.54 USD, real support/resistance. Updated 2026-09-11.
Frequently asked questions
What sector is BBLG in?
Bone Biologics (BBLG) is classified under Healthcare (Biotechnology), listed on NASDAQ, US.
Is BBLG in an uptrend or downtrend?
As of 2026-09-11, BBLG is in a range — insufficient history for 200-DMA. See the full technical research page for support and resistance levels.
What is BBLG's trailing P/E ratio?
BBLG's trailing P/E is -0.40, with a market cap of 0.00B. See the earnings research page for full valuation detail.
When does BBLG next report earnings?
BBLG is next scheduled to report earnings on 2026-08-13, with a consensus EPS estimate of -0.39 USD.